Although targeting the immune checkpoint alone showed somewhat discouraging clinical outcomes, the simultaneous inhibition of the immune checkpoint and VEGF revealed unprecedented clinical efficacy in HCC patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.